In particular, Nup93 might represent an attractive new therapeutic target because Nup93 mutations can increase both cell migration and the expression of epithelial to mesenchymal transition (EMT) markers in breast cancer (Lee et al, 2016). This evidence concerns the gene NUP93 and breast carcinoma.